Figure 1.

Kaplan-Meier survival distributions of elderly glioblastoma patients stratified for age, WHO performance status (PS), and MGMT promoter methylation. Patients in younger age groups (A), lower PS at diagnosis (B) and methylated MGMT status (C) were observed to have significantly longer median OS compared to their respective controls. Survival distributions were compared using pairwise log-rank test (D). mOS, median overall survival; PS, WHO performance status; 95%CI, 95% confidence intervals.